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Because of the propensity of the 20-kDa variant of human growth hormone (GH) to aggregate with itself 
and with 22-kDa human GH, it has been difficult to prepare monomeric 20-kDa GH in highly purified form. 
This has been a major complicating factor in determining whether 20-kDa GH has a biological activity 
profile distinct from that of 22-kDa GH. In the present study, native 20-kI)a GH was isolated from a human 
GH dimer concentrate and purified by a procedure that included column electrophoresis in agarose 
suspension as a final separation step. This procedure yielded highly purified monomeric 20-kDa GH, which 
was contaminated to an extent of less than 1% with 22-kDa GH, and which exhibited only a small degree of 
dimerization upon storage. The native 20-kDa GH was quite active in stimulating growth in hypophysecto- 
mized rats, when growth was assessed by body weight gain, longitudinal bone growth, the stimulation of 
sulfation of cartilage, and the elevation of serum IGF-1 level. However, in all of these growth assays, the 
20-kDa GH was somewhat less active than the native 22-kDa GH to which it was compared; e.g., in the body 
weight gain and longitudinal bone growth assays, it had an estimated potency of 0.6 relative to the 22-kDa 
GH. The 20-kDa GH exhibited substantial diabetogenic activity when tested for the ability to raise fasting 
blood glucose concentration and to impair glucose tolerance in o h ~ o h  mice. Also, the native 20-kDa GH 
had significant in vitro insulin-like activity, although its potency was approximately 20% that of the native 
22-kDa GH to which it was compared. Thus, the biological activity profile of native 20-kDa GH differs from 
that of 22-kDa GH primarily in that insulin-like activity is markedly attenuated. 
Introduction 
A variety of structurally modified forms of 
growth hormone (GH) have been isolated from 
the human pituitary gland. The predominant 
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monomeric form of the hormone present in the 
gland consists of a single peptide chain of 191 
amino acid residues, having a molecular size of 
approx. 22 kDa. About 10% of the total G H  in the 
human pituitary is a 20-kDa variant lacking re- 
sidues 32-46 of the amino acid sequence [1-5]. 
This variant occurs because the nucleotides encod- 
ing sequence 32-46 are occasionally deleted dur- 
ing the conversion of G H  pre-mRNA to GH 
mRNA [6]. Because of its propensity to aggregate 
with itself and with 22-kDa GH, 20-kDa G H  
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exists in human pituitary extracts primarily in 
various dimeric forms [2,5]. As a consequence, it 
has been quite difficult to prepare monomeric 
20-kDa GH in highly purified form. This has been 
a maj.or complicating factor in determining 
whether 20-kDa G H  has a biological activity pro- 
file distinct from that of 22-kDa GH. 
It has been reported previously [2,7] that native 
20-kDa GH is equipotent with 22-kDa GH in 
stimulating growth in the hypophysectomized rat, 
and that it has lactogenic activity in the pigeon 
crop sac assay equivalent to that of 22-kDa GH  
[2]' However, it has been claimed [7,8] that native 
20-kDa GH lacks significant diabetogenic and 
insulin-like activities, which are intrinsic proper- 
ties of 22-kDa GH. This conclusion was based on 
the findings that a native 20-kDa GH preparation 
(a) failed to cause hyperglycemia and glucose in- 
tolerance in the dog when given 10 h prior to a 
glucose tolerance test [7], (b) did not produce 
hypoglycemia or decrease plasma free fatty acids 
when administered acutely to hypophysectomized 
rats [8], and (c) failed to increase glucose oxida- 
tion by isolated rat adipose tissue [8]. This conclu- 
sion has been challenged in recent reports demon- 
strating that bacterially derived biosynthetic hu- 
man 20-kDa methionyl-GH had both diabetogenic 
[9] and insulin-like activities [9,10], although the 
latter was approximately 20% that of biosynthetic 
human 22-kDa methionyl-GH [9]. 
The present study describes the biological char- 
acterization of a native 20-kDa GH preparation 
that was isolated by a procedure similar to that 
used by Singh and Lewis [4], but which included a 
final electrophoretic step. This procedure yielded a 
highly purified preparation of native 20-kDa GH 
having less than 1% contamination with 22-kDa 
GH. 
Materials and Methods 
Preparation of 20-kDa GH 
The starting material for the isolation of 20-kDa 
G H  monomer was a human GH dimer con- 
centrate obtained as a side fraction during the 
preparation of 22-kDa GH (Crescormon ®) at 
KabiVitrum AB, according to the method of Roos 
et al. [11]. About 2.5 g of dimer concentrate in a 
volume of 2 1, which had been prepared from 4000 
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human pituitary glands, were utilized. As a first 
step, the concentrate was dialyzed against 0.005 M 
potassium phosphate buffer (pH 7.0) and then 
applied to a 5 x 22 cm column of SP-Sephadex 
C-50 (Pharmacia, Uppsala, Sweden) to remove 
human thyrotropic hormone. The column was run 
at a flow rate of 40 ml /h ,  and 17-ml fractions 
were collected. The column was eluted by increas- 
ing buffer concentration stepwise, while maintain- 
ing constant pH. The thyrotropic hormone was 
adsorbed on the SP-Sephadex and was later re- 
covered from the column by elution with 0.06 M 
potassium phosphate buffer [12]. The GH dimer 
material passed through the column unretarded 
and was transferred directly to a second column 
(2 x 56 cm) packed with DEAE-Sepharose CL-6B 
(Pharmacia), which was coupled to the SP-Seph- 
adex column by plastic tubing. The DEAE-Seph- 
arose column had been equilibrated with 0.005 M 
potassium phosphate buffer (pH 7.0). The col- 
umns were then disconnected, and the dimer 
material was eluted from the DEAE-Sepharose 
column with 0.5 M potassium phosphate buffer 
(pH 7.0). This step concentrated the dimer frac- 
tion 25-fold, making it possible to proceed to 
molecular sieve chromatography directly. 
The concentrated dimer fraction was divided 
into two equal portions of 29 ml (700 mg), and 
each was applied to a separate 3.2 x 150 cm col- 
umn of Sephadex G-100 (Pharmacia) that had 
been equilibrated with 0.05 M ammonium bi- 
carbonate. The columns were then eluted with this 
same solution at a flow rate of 25 ml/h ,  and 10-ml 
fractions were collected. Most of the material ap- 
plied appeared as dimer. About 8% was high- 
molecular-mass material, and 16% was 22-kDa 
GH. No 20-kDa G H  was detectable in the de- 
scending part of the monomer 22-kDa GH peak, 
as reported earlier by Singh and Lewis [4]. The 
fractions containing the G H  dimer material were 
pooled and lyophilized. The heterogeneity of this 
dimer material is apparent in its SDS-poly- 
acrylamide gel electrophoresis pattern (Fig. 1, lane 
2) and its analytical isoelectric focusing pattern 
(Fig. 2, lane 2). 
The lyophilized dimer material was then sub- 
mitted to ion-exchange chromatography in the 
presence of urea, which splits noncovalent dimers 
to monomers and increases the charge differences 
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Fig. 1. Analytical SDS-polyacrylamide gel electrophoresis of 
(1) 22-kDa GH, (2) GH dimer from Sephadex G-100 chro- 
matography, (3) pooled material (peak 3) from chromatogra- 
phy on DEAE-Sepharose CL-6B in 6M urea, and (4) the final 
20-kDa GH pool from zone electrophoresis in agarose suspen- 
sion. 
between 20-kDa GH and 22-kDa GH. The 
material was dissolved in 6 M urea (analytical 
grade, Merck, Darmstadt, F.R.G.), and the con- 
ductivity of the solution was adjusted to 1.1 mmho 
with solid ammonium bicarbonate. The sample 
(700 mg) was then applied to a 2 X 23 cm column 
packed with DEAE-Sepharose CL-6B that had 
been equilibrated with 6 M urea-ammonium bi- 
carbonate buffer (1.1 mmho). All urea-ammonium 
bicarbonate solutions used in this procedure were 
passed through 0.2-~m filters and were used im- 
mediately. The column was washed with the above 
urea-ammonium bicarbonate buffer, and then the 
material bound to the column was eluted by in- 
creasing the conductivity of the elution buffer in a 
steep, stepwise fashion (from 1.1 to 5.0 mmho) by 
the addition of solid ammonium bicarbonate. The 
Fig. 2. Analytical isoelectric focusing in agarose gel (pH 
4.0-6.5) of (1) 22-kDa GH, (2) GH dimer from Sephadex 
G-100 chromatography, (3) pooled material (peak 3) from 
chromatography on DEAE-Sepharose CL-6B in 6M urea, and 
(4) the final 20-kDa GH pool from zone electrophoresis in 
agarose suspension. 
elution pattern obtained is shown in Fig. 3. Four 
relatively sharp peaks were obtained. Peak 1 was 
contaminated with high-molecular mass materials. 
Peaks 2 and 3 were both primarily 20-kDa GH, 
and peak 4 was 22-kDa GH. When the conductiv- 
ity of the elution buffer was subsequently raised to 
10 mmho, covalent dimeric GH was eluted from 
the column. The recovery of 20-kDa GH in peaks 
2 and 3 amounted to a total of 48 mg. Analysis of 
individual fractions in those peaks by SDS-poly- 
acrylamide gel electrophoresis indicated con- 
tamination with 22-kDa GH in the range of 
3-10%, depending upon the particular fraction 
examined (see Fig. 1, lane 3). The SDS-poly- 
acrylamide gel electrophoresis patterns of frac- 
tions from peak 2 and peak 3 were similar. Whether 
peak 2 contains an isoform of 20-kDa GH or 
represents overlapping material from peak 3 re- 
mains to be answered. It should be noted here that 
in the previous work of Singh and Lewis [4] a less 
steep increase in the conductivity of the elution 
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Fig. 3. Chromatography on DEAE-Sepharose CL-6B of GH 
dimer from molecular sieve chromatography. The buffer was 6 
M urea adjusted to a conductivity of 5.0 mmho with solid 
ammonium bicarbonate. Flow rate was 40 ml/h,  and fraction 
size was 10 ml. The hatched area (peak 3) represents the 
20-kDa GH-containing fractions that were utilized for further 
purification. 
peak, having less than 5% contamination with 
22-kDa GH, as judged by SDS-polyacrylamide gel 
electrophoresis. 
In a final separation step, the pooled and ultra- 
filtered fractions corresponding to peak 3 in the 
DEAE-Sepharose chromatogram (Fig. 3) were 
subjected to column electrophoresis in agarose 
suspension according to the method of Hjert~n 
[13]. The 22-kDa GH contamination of this pool 
was about 7%. The electrophoresis was performed 
in 0.15 M glycine-sodium hydroxide buffer (pH 
8.8) which also contained 6 M urea. Because of 
the presence of urea, the content of agarose 
(Agarose C, Pharmacia) had to be increased to 
0.30% (w/v), which is approximately twice that 
normally used. The solid urea was added to the 
boiled agarose suspension after it had cooled to 
50 ° C. The agarose suspension was then left over- 
night to cool and stabilize. The gel which formed 
was broken by gentle stirring and poured into the 
electrophoresis tube (1.0 x 65 cm). The con- 
centrated sample (11 mg in 0.7 ml), which was 
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stabilized by being mixed with the pellet from a 
1.05-ml aliquot of the agarose suspension that had 
been centrifuged, was applied close to the cathode. 
Electrophoresis was carried out for 30000 V-h. 
The column was then emptied from the top by 
sucking out fractions of approx. 0.8 ml each with 
a thin plastic tube. The distribution of protein 
among the fractions was determined by measuring 
the difference in their absorbance at 280 and 310 
nm [14]. The agarose was removed from the frac- 
tions by centrifugation at 40000 x g for 1 h at 
4 ° C. The 20-kDa GH-containing fractions, as de- 
termined by SDS-polyacrylamide gel electrophore- 
sis, were then pooled. SDS-polyacrylamide gel 
electrophoresis of this 20-kDa GH pool prior to 
lyophilization is shown in Fig. 1 (lane 4). It is 
clear that the zone gel electrophoresis step gave a 
very effective separation of 20-kDa GH from 22- 
kDa GH. When this material was submitted to 
polyacrylamide gel electrophoresis in the absence 
of SDS or 2-mercaptoethanol, the 20-kDa GH 
migrated as monomer, indicating a complete and 
lasting conversion of the substance to monomeric 
form. 
The 20-kDa GH pool was dialyzed against 
0.005 M ammonium bicarbonate and lyophilized. 
To eliminate salt completely, the lyophilized 
material was suspended in 0.001 M ammonium 
bicarbonate and relyophilized. Analysis of the 
lyophilized 20-kDa GH preparation indicated that 
it was contaminated to an extent of less than 1% 
with 22-kDa GH. Supporting evidence for the 
homogeneity of this 20-kDa GH preparation was 
obtained by submitting it to analytical isoelectric 
focusing (see Fig. 2, lane 4). The lyophilized pre- 
paration was submitted to polyacrylamide gel 
electrophoresis in the absence of SDS and 2- 
mercaptoethanol after storage for 2 months at 
4°C in the dry form and subsequently for 6 
months at - 20  °C as a frozen solution (1 mg/ml 
in 0.001 M ammonium bicarbonate). Scanning the 
stained gels at 560 nm revealed the presence of 
only about 15% dimeric material. This suggests 
that this preparation of 20-kDa GH is more stable 
upon storage than that made earlier [4] by some- 
what different methods. 
Polyacrylamide gel electrophoresis in the pres- 
ence or absence of SDS and 2-mercaptoethanol 
was carried out according to the methods of Ne- 
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ville [15]. The composition of the gel was T = 18.5% 
and C = 1% (the notation of Hjert6n [16]), and the 
buffers used were chosen to obtain a pH of 10.50. 
The gels were stained with Coomassie brilliant 
blue in a solution of 50% methanol /7% acetic 
acid and destained in a solution of 10% 
methanol /7% acetic acid. Isoelectric focusing in 
agarose gel was performed with equipment manu- 
factured by Pharmacia according to methods pro- 
vided by the supplier. Pharmalyte ® (pH 4.0-6.5) 
was used, and approx. 2-#g samples were applied. 
After termination of isoelectric focusing, the pro- 
teins were visualized by silver staining [17]. 
Protein concentration was estimated throughout 
by measuring absorbance at 280 nm in a 1 cm cell. 
1 unit of absorbance was assumed to correspond 
to a protein concentration of 1 mg/ml.  
The purification procedure was guided in part 
by radioimmunoassays performed with a double 
antibody technique. 
Assays for growth-promoting activity 
Two comprehensive growth studies (experi- 
ments 1 and 2) were conducted in the following 
manner. Hypophysectomized male rats (80-100 g 
body weight) of the Sprague-Dawley strain were 
purchased from Mollegaard Breeding Labs, Den- 
mark, and were used for experiments 2 weeks after 
the operation. On the first day of the experiment, 
each animal received an intraperitoneal injection 
of 0.8 mg of tetracycline (Terramycin ®, Pfizer) in 
0.5 ml saline for the subsequent measurement of 
longitudinal bone growth [18-20]. They were also 
given a subcutaneous injection of 40 /~g cortisone 
acetate (Upjohn) in 0.5 ml saline. On this day, 
each animal was also lightly anesthetized with 
diethyl ether, and a blood sample was taken from 
the retroorbital plexus to obtain serum, which was 
frozen for subsequent analysis of IGF-1 level. On 
days 2 and 3, the injections of cortisone acetate 
were repeated. On days 4 and 5, each rat received 
an intraperitoneal injection of 10 /~g of L-thyrox- 
ine (Sigma) in 0.5 ml saline that had been made 
alkaline with NaOH. On days 6-15 of the experi- 
ment, the animals received two daily subcutaneous 
injections (morning and late afternoon) of 0.5 ml 
of either vehicle, native 22-kDa GH or native 
20-kDa G H  (6 or 60 /~g/day). On day 6, each 
animal was again anesthetized with diethyl ether, 
and another blood sample was taken for the mea- 
surement of IGF-1 [21]. On day 15, all animals 
received an intraperitoneal injection of [35S]sulfate 
for the measurement of sulfate incorporation into 
cartilage, as described previously by Skottner et al. 
[22]. On the following day, a final blood sample 
was obtained for the measurement of IGF-1 level, 
and the animals were then decapitated, and vari- 
ous tissues were removed for analysis. 
The native 22-kDa GH used in the growth-pro- 
moting assays was Crescormon ® (KabiVitrum AB) 
(3 IU/mg) ,  which had been desalted on PD-10 
columns (Pharmacia) that were equilibrated with 
0.1 M ammonium bicarbonate. The protein con- 
centration of the desalted hormone solution was 
estimated by measuring its absorbance at 280 nm, 
assuming an absorption coefficient (A280, 0.1% 
(w/v)  solution, 1 cm) for 22-kDa GH of 0.76. 
(This absorption coefficient for 22-kDa GH was 
empirically determined. Corrected ultraviolet 
spectra of desalted sample solutions were com- 
pared to their protein contents estimated from the 
amino acid composition of lyophilized, hydrolysed 
samples.) The hormone solution was then diluted 
with saline, and aliquots of the diluted solution 
were frozen. Fresh aliquots of frozen hormone 
were thawed and used immediately for each injec- 
tion. The 20-kDa G H  used for the growth-promo- 
ting assays was an aliquot of the final 20-kDa GH 
pool. For the first growth study (experiment 1), a 
sample of the final 20-kDa GH pool was frozen 
and maintained at - 7 0  °C until it was diluted for 
use in experiments. The protein concentration of 
this solution was estimated by measuring its ab- 
sorbance at 280 nm, assuming an absorption coef- 
ficient of 0.70 (as determined for 22-kDa GH). 
The somewhat lower absorption coefficient is con- 
sistent with the loss of two tyrosine residues in the 
deletion peptide 32-46, and is in accord with the 
previous observation of Chapman et al. [5] show- 
ing about a 10% difference in the absorption coef- 
ficients of 22-kDa GH and 20-kDa GH. The 
20-kDa GH solution was diluted with saline, and 
aliquots were frozen. Fresh aliquots of frozen 20- 
kDa G H  were thawed and used immediately for 
each injection. For experiment 2, a sample of the 
final 20-kDa GH pool was divided into aliquots, 
and these were then lyophilized individually. Each 
morning, a lyophilized aliquot of the 20-kDa G H  
was dissolved in saline and used for injections 
immediately. The remainder of the aliquot was 
refrozen and stored at - 70 o C until the afternoon, 
when it was thawed and used for the second series 
of injections. 
The potency of the 20-kDa GH relative to that 
of 22-kDa GH in stimulating weight gain and 
longitudinal bone growth was estimated using a 
parallel line bioassay program [23]. 
Assay for diabetogenic activity 
The diabetogenic activity of the native 20-kDa 
GH was assessed in female ob/ob mice as previ- 
ously described in detail [24,25]. The final re- 
lyophilized preparation of the 20-kDa GH was 
used for these experiments (see above), and the 
doses of hormone given were based on actual 
weight of the dried hormone. A fresh solution of 
the hormone was used each day for the injections. 
The hormone was dissolved in distilled water made 
slightly alkaline with NaOH and administered in a 
volume of 0.1 ml immediately after being dis- 
solved. Statistical comparisons were made using 
the paired t-test, and effects were considered to be 
significant at the P < 0.05 level. Statistically sig- 
nificant diabetogenic effects are routinely ob- 
tained in this assay with 10-25/~g of highly puri- 
fied native 22-kDa GH [25-27]. 
Assay of insulin-like activity 
The 20-kDa GH was tested for in vitro insulin- 
like activity by assessing its ability to stimulate 
[14C]glucose oxidation to 14CO2 by isolated epidi- 
dymal adipose tissue from hypophysectomized 
rats, as previously described in detail [28]. The 
activity of the 20-kDa GH was compared to that 
of purified native human GH monomer (1.1 
IU/mg) isolated and purified by ion-exchange 
chromatography as previously described [29]. Stat- 
istical comparisons were made with Dunnet's test, 
and a difference was considered significant if P < 
0.05. 
Results 
The ability of the purified native 20-kDa GH to 
stimulate body weight gain in hypophysectomized 
rats compared to that of 22-kDa GH is shown in 
Table I. It can be seen that, like 22-kDa GH, 
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20-kDa GH stimulated body weight gain in a 
dose-dependent manner during the course of 
treatment in both experiments 1 and 2. In both 
experiments, however, 20-kDa GH generally pro- 
duced smaller mean net changes in body weight 
than did 22-kDa GH at both the 6 and 60 ~tg daily 
doses used. When the data were analysed using a 
parallel line bioassay program, the potency of the 
20-kDa GH relative to that of the 22-kDa GH in 
experiment 1 was 0.54 (0.35-0.80, 95% confidence 
limits) and in experiment 2 was 0.60 (0.44-0.81). 
The effects of 20-kDa GH on longitudinal bone 
growth and tibial epiphyseal width are compared 
with those of 22-kDa GH in Table II. The 20-kDa 
GH behaved like 22-kDa GH in stimulating longi- 
tudinal bone growth and increasing tibial epi- 
physeal width in a dose-dependent fashion. Again, 
in both experiments, 20-kDa GH appeared to be 
somewhat less effective than 22-kDa GH in 
stimulating both longitudinal bone growth and 
tibial epiphyseal width. When the data for longitu- 
dinal bone growth were analysed using the parallel 
line bioassay program, the potency of the 20-kDa 
GH relative to that of the 22-kDa GH in experi- 
ment 1 was 0.50 (0.23-0.92) and in experiment 2 
was 0.62 (0.35-1.04). Thus, the estimated potency 
of 20-kDa GH in this assay was quite similar to 
that found in the body weight gain studies de- 
scribed above. 
Table III summarizes the results obtained with 
20-kDa GH and 22-kDa GH on [35S]sulfate incor- 
poration into various cartilages of the hypo- 
physectomized rat. In the case of all four carti- 
lages examined (costal, xiphoid, proximal tibia 
and proximal femur), both hormones stimulated 
[35S]sulfate incorporation in a dose-dependent 
manner, and, again, the 20-kDa GH appeared to 
be somewhat less effective in stimulating sulfation 
than was 22-kDa GH. 
Various organs, including the liver, lungs, kid- 
neys, heart and testes, were removed from the 
20-kDa GH- and 22-kDa GH-treated rats on the 
final day of the experiment, and their wet weights 
were compared. Both hormones increased the wet 
weight of all of these organs over those of the 
vehicle-treated controls (data not shown). 
Last, Table IV summarizes the effects of the 
course of treatment with 20-kDa GH and 22-kDa 
GH on the concentration of IGF-1 in the serum of 
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TABLE I 
EFFECTS OF NATIVE 22-kDa GH AND NATIVE 20-kDa GH ON BODY WEIGHT GAIN BY HYPOPHYSECTOMIZED 
RATS 
Treatment with 22-kDa or 20-kDa GH was begun on day 6 of the experiment, and the last hormone injection was given on day 15. 
The values given are the net changes in body weight in g from body weights measured on day 6. Values represent the mean +_ S.E. of n 
observations. 
Treatment n Net change in body weight (g) 
day 8 day 10 day 13 day 16 
Experiment 1 
Vehicle 7 2.4 _+ 0.3 5.3 + 0.6 8.4 -+ 0.8 9.4 _+ 0.8 
22-kDa GH 
6 #g /day  6 5.7 _+ 0.7 13.3 _+ 1.2 20.0 _+ 1.0 25.0 -+ 1.5 
60 bt g /day  7 10.6 + 0.5 22.9 + 0.7 36.6 _+ 1.2 48.1 _+ 2.3 
20-kDa GH 
6 #g /day  7 6.0-+0.6 12.1 +0.6 19.3-+0.6 21.6-+ 1.0 
60 #g /day  7 8.9-+0.8 20.0_+ 1.3 32.0_+ 1.7 41.1 _+ 1.9 
Experiment 2 
Vehicle 6 3.2 _+ 0.6 7.5 _+ 0.6 10.7 _+ 0.6 ! 2.7 _+ 0.8 
22-kDa GH 
6 #g /day  5 7.4 _+ 1.2 17.0 _+ 0.5 24.6 _+ 1.0 27.0 _+ 1.1 
60 # g / d a y  6 11.2 +_ 0.8 23.8 _+ 1.1 37.8 _+ 1.5 48.7 _+ 1.6 
20 kDa GH 
6 # g /day  6 5.3 + 0.2 13.3 _+ 0.4 19.5 _+ 0.6 22.8 _+ 0.6 
60 # g / d a y  6 10.7 -+ 0.4 23.8 _+ 0.6 35.3 _+ 0.6 43.5 _+ 1.6 
TABLE I1 
EFFECTS OF NATIVE 22-kDa GH AND NATIVE 20-kDa 
GH ON LONGITUDINAL TIBIA GROWTH AND TIBIA 
EPIPHYSEAL WIDTH OF HYPOPHYSECTOMIZED RATS 
Values represent the mean-+ S.E. of n observations. 




Vehicle 3 816 _+ 101 215 -t- 4 
22-kDa GH 
6 #g /day  3 1417_+101 308_+ 7 
60 # g / d a y  6 1851 _+ 38 373_+ 7 
20-kDa GH 
6 # g / d a y  5 1285_+ 63 291_+ 7 
60 # g / d a y  4 1 738_+ 26 360_+ 10 
Experiment 2 
Vehicle 6 599-+ 26 181-+ 7 
22-kDa 
6 # g / d a y  5 1133-+ 51 231_+ 4 
6 0 # g / d a y  3 1512-+ 18 282_+ 5 
20-kDa GH 
6 #g /day  5 1034-+ 41 210_+10 
6 0 # g / d a y  4 1437_+ 21 248_+ 8 
the hypophysectomized rats, as measured by a 
radioreceptor assay that detects both free and 
protein-bound IGF-1. On day 1 of both experi- 
ments, all animals within a given experiment had 
IGF-1 levels that were roughly equivalent, al- 
though the starting values in experiment 2 were 
approximately twice those in experiment 1. By day 
6, the IGF-1 levels of all groups had approxi- 
mately doubled, most probably due to the thyrox- 
ine administered on days 4 and 5 [22]. The course 
of treatment with 6 /~g/day of either 20-kDa or 
22-kDa G H  had little further effect on IGF-1 
levels, and, in any event, the mean values on day 
16 were equivalent for 20-kDa GH-  and 22-kDa 
GH-trea ted  animals. At a dose of 60 ~ g / d a y ,  
both 20-kDa and 22-kDa G H  produced signifi- 
cant increases in IGF-1 level over that existing on 
Day 6 of the studies. However, in both experi- 
ments, the percent increase in IGF-1 level over the 
mean value on Day 6 was greater in 22-kDa 
GH-treated rats than in the 20-kDa GH-treated 
animals (see Table IV), suggesting again that the 
20-kDa G H  was somewhat less potent than 22-kDa 
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TABLE III 
EFFECTS OF NATIVE 22-kDa GH AND NATIVE 20-kDa GH ON [35S]SULFATE INCORPORATION INTO VARIOUS 
CARTILAGES OF HYPOPHYSECTOMIZED RATS 
Values represent the mean +_ S.E. of n observations. 
Treatment n 35 [ S]Sulfate incorporation (dpm/mg dry weight) 
costal xiphoid proximal tibia proximal femur 
Experiment 1 
Vehicle 7 311 _+ 23 889 +_ 101 346_+ 29 315 +_ 22 
22-kDa GH 
6 #g/day 6 642 _+ 55 1514_+ 156 619 +_ 75 618 _+ 54 
60 bt g/day 7 1 256 +_ 124 2 579 _+ 356 934 _+ 98 1 012 _+ 67 
20-kDa GH 
6/L g/day 7 497 +- 48 1204 _+ 211 438 _+ 25 501 _+ 32 
60/~ g/day 7 1024 _+ 121 2029 _+ 235 719 _+ 53 826 _+ 62 
Experiment 2 
Vehicle 6 139+- 9 209_+ 25 154_+27 120_+10 
22-kDa GH 
6 t~g/day 5 291 +_ 12 520_+ 43 223 +_ 42 201 +_ 12 
60 t~g/day 6 545 _+ 34 817 _+ 84 376_+ 21 301 _+ 13 
20-kDa GH 
6 t~g/day 6 256_+ 16 435 _+ 47 260_+ 24 179_+ 10 
60/tg/day 6 369_+ 36 554_+ 49 269_+23 233+21 
TABLE IV 
EFFECTS OF NATIVE 22-kDa GH AND NATIVE 20-kDa 
GH ON IGF-1 LEVELS IN SERUM FROM HYPO- 
PHYSECTOMIZED RATS 
Values represent the mean_+ S.E. of n observations. 
Treatment n IGFlevel by radioreceptor assay 
(U/ml) 
day 1 day 6 day 16 
Experiment 1 
Vehicle 7 0.94+0.16 2.09+_0.31 1.36_+0.15 
22-kDa GH 
6 #g/day 6 1.28_+0.27 2.03+0.37 2.18+_0.38 
60 btg/day 7 1.03+_0.08 2.28+_0.26 7.63+_1.12 
20-kDa GH 
6 btg/day 7 1.32+_0.09 2.44+_0.31 1.96_+0.35 
60t~g/day 7 0.99+_0.14 2.31 _+0.29 4.13 _+0.33 
Experiment 2 
Vehicle 6 2.54_+0.22 4.41_+0.57 3.05_+0.20 
22-kDa GH 
6 ~g/day 5 2.40+_0.41 4.62_+0.78 3.92+_0.29 
60~tg/day 6 1.78+_0.37 4.80+_0.61 8.70+0.72 
20-kDa GH 
6/~g/day 6 2.40_+0.31 6.56+_0.35 3.64_+0.29 
60t~g/day 6 2.44_+0.29 6.10+_0.51 8.45+0.85 
G H  in this assay for growth-promot ing activity. 
The native 20-kDa G H  was tested for diabeto-  
genic activity by examining  its abili ty to raise 
fasting blood glucose concent ra t ion  and  decrease 
glucose tolerance when injected chronical ly into 
ob/ob mice. Fig. 4 il lustrates the results ob ta ined  
when ~20-kDa G H  was tested for diabetogenic  
activity at doses of 5, 10, 25 or 5 0 / ~ g / d a y  for 3 
days. When  20-kDa G H  was adminis tered at a 
dose of 5 /~g/day,  it had no effect on either 
fasting b lood glucose concent ra t ion  or glucose 
tolerance (see Fig. 4A). When  the dose was in- 
creased to 10 / t g / d a y ,  there was again no effect 
on  fasting blood glucose concentra t ion,  bu t  a 
modest  decrease in glucose tolerance was observed 
(Fig. 4A). When  the dose of 20-kDa G H  was 
raised to 25 /~g/day,  both  an increase in fasting 
b lood glucose and  a decrease in glucose tolerance 
were obta ined  (Fig. 4B). Large changes in both  
fasting blood glucose concent ra t ion  and  glucose 
tolerance were ob ta ined  when 20-kDa G H  was 
adminis tered  at a dose of 50 ~ tg /day  (Fig. 4B). 
This  dose response relat ionship is similar to that 
rout inely  obta ined  in our  laboratory with purif ied 
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Fig. 4. Effects of treatment with 5 or 10 #g/day of 20-kDa GH (A) and 25 or 50/~g/day of 20-kDa GH (B) on glucose tolerance in 
fasted ob/ob mice. Each point represents the mean of n observations. Vertical lines through the points indicate 2 S.Es. The effects of 
the 10/~g/day dose of 20-kDa GH were significant (P < 0.05) at the 60 and 90 min time points. The effects of the 25 and 50/~g/day 
doses of 20-kDa GH were statistically significant at all time points examined. 
The in vitro insulin-l ike activity of the purified 
native 20-kDa G H  prepara t ion  is compared with 
that of nat ive 22-kDa G H  in Table  V. Purified 
22-kDa G H  produced statistically significant in- 
creases in [14C]glucose oxidat ion to 14C02 by iso- 
lated rat epididymal  adipose tissue when em- 
ployed at concent ra t ions  of 2 or 10 nM. On the 
other hand,  5 times the concent ra t ion  of 20-kDa 
G H  (10 or 50 nM) was required to produce re- 
sponses comparable  to those obtained with 2 or 10 
n M  22-kDa GH.  Thus, native 20-kDa G H  has 
intr insic  in vitro insulin-l ike activity, but  this ac- 
tivity is considerably  less than that of native 22- 
kD a  GH.  
TABLE V 
IN VITRO EFFECTS OF NATIVE 22-kDa GH AND NA- 
TIVE 20-kDa GH ON [14C]GLUCOSE OXIDATION BY 
EPIDIDYMAL ADIPOSE TISSUE OF HYPOPHYSECTO- 
MIZED RATS 
Values represent the mean_+ S.E. of n observations. * Signifi- 
cantly different from the control (P < 0.05). 
Material Conc. t/ 14C02 production 




22 36.6 + 2.6 
0.4 7 32.0 + 2.2 
2 21 54.3 + 3.6 * 
10 15 86.2+9.6 * 
2 6 33.1 + 3.0 
10 20 50.8+4.2 * 
50 14 75.4_+5.2 * 
Discussion 
In the past, it has been difficult to isolate native 
20-kDa G H  in monomeric form, free of signifi- 
cant contamination with 22-kDa GH. As a conse- 
quence, at tempts to determine whether 20-kDa 
G H  has a biological activity profile distinct from 
that of 22-kDa G H  have been compromised. In 
the present study, a method was devised for the 
purification of monomeric 20-kDa G H  from hu- 
man pituitary glands, which utilized column elec- 
trophoresis in agarose gel as a final purification 
step. This procedure yielded a highly purified 
monomeric preparation of 20-kDa GH, which was 
contaminated to an extent of less than 1% with 
22-kDa GH.  Moreover, this preparation of 20-kDa 
G H  appeared to be reasonably stable, since it 
exhibited only a small degree of dimerization upon 
storage for several months. Thus, the availability 
of this preparation of native 20-kDa G H  afforded 
an opportunity to determine whether the bio- 
logical properties of 20-kDa G H  differ in any 
significant respect from those of 22-kDa GH.  
In agreement with previous reports [2,7], the 
native 20-kDa G H  preparation was found to 
possess considerable activity in stimulating growth 
in the hypophysectomized rat, when growth was 
assessed in a variety of ways. However, it was 
somewhat less active than the native 22-kDa G H  
preparation to which it was compared in all of the 
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tests for growth that were used. When the data 
obtained in the body weight gain and longitudinal 
bone growth assays were submitted to analysis 
using a parallel line bioassay program, the esti- 
mated potency of the 20-kDa G H  was 0.6 that of 
the 22-kDa G H  preparation. Considering that the 
22-kDa G H  used has an estimated growth potency 
of 3 I U / m g ,  the 20-kDa G H  would then have a 
potency of approximately 1.8 I U / m g .  This is 
within the range of potencies (0.9-1.8 I U / m g )  
recorded for various native 20-kDa G H  prepara- 
tions in the weight gain assay by Lewis et al. [2]. 
Whether the substantial growth-promoting activ- 
ity observed here and in previous studies is, indeed, 
due to high intrinsic activity of the 20-kDa G H  
molecule has been questioned recently by Bau- 
mann et al. [30]. Since 20-kDa G H  has been found 
to interact poorly in some but not all receptor 
assays for GH,  compared to 22-kDa G H  (for 
review, see Ref. 31), these investigators proposed 
that the high growth-promoting activity of 20-kDa 
G H  results from its slow clearance from the circu- 
lation. Indeed, Baumann et al. [30] demonstrated 
that the metabolic clearance rate of 20-kDa G H  in 
the rat is significantly slower than that of 22-kDa 
GH.  However, it is possible that the low degree of 
binding of 20-kDa G H  observed in certain recep- 
tor assays and the apparent  slow rate of metabolic 
clearance of the variant are, in fact, due to its 
great propensity to aggregate, as discussed earlier. 
Thus, these findings may or may not have bearing 
on the question of the degree of intrinsic growth- 
promoting activity possessed by 20-kDa GH. 
The native 20-kDa G H  preparation exhibited 
substantial diabetogenic activity when tested for 
the ability to raise fasting blood glucose con- 
centration and impair glucose tolerance in ob/ob 
mice. These results are in accord with recent ob- 
servations [9] demonstrating that biosynthetic hu- 
man 20-kDa methionyl-GH is diabetogenic, thus 
establishing with certainty that diabetogenic activ- 
ity is an intrinsic property of the 20-kDa variant 
of human GH.  Moreover, the native 20-kDa G H  
preparat ion exhibited significant in vitro insulin- 
like activity, although its potency was consider- 
ably lower than that of native 22-kDa GH.  This 
observation again agrees with recent findings [9] 
employing biosynthetic human 20-kDa methionyl- 
GH,  which indicated that the latter possessed 20% 
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of the in vitro insul in- l ike activity of biosynthet ic  
h u m a n  22-kDa meth iony l -GH.  Thus, insul in-l ike 
activity is also an intr insic  proper ty  of 20-kDa 
GH.  Its a t tenuated  insul in- l ike activity may reflect 
either that the deleted sequence (residues 32-46)  
is par t  of the active site for this activity of G H  or 
that the altered conformat ion  of 20-kDa G H  may 
interfere with the expression of its insul in-l ike 
activity, as has recently been proposed [9]. 
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